
Announcement
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)
Learn MoreAnnouncement
Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab-aacf)
Learn MoreAnnouncement
Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend® (pegfilgrastim-fpgk)
Fresenius Kabi’s first approved U.S. biosimilar.
Learn MoreFresenius Kabi’s first approved U.S. biosimilar.
Webinar
Adopting Biosimilars in Oncology Practice: A Panel Discussion
Watch expert speakers discuss the current and future oncology biosimilar landscape.
Learn MoreWatch expert speakers discuss the current and future oncology biosimilar landscape.
Upcoming Event
ASCO Scientific Program / June 2-6, 2023
Come see us in Chicago at the American Society of Clinical Oncology Scientific Program.
Learn MoreCome see us in Chicago at the American Society of Clinical Oncology Scientific Program.
Upcoming Event
ASHP Summer Meeting / June 10-14, 2023
Join us in Baltimore at the American Society of Health-System Pharmacists Summer Meeting.
Learn MoreJoin us in Baltimore at the American Society of Health-System Pharmacists Summer Meeting.
Upcoming Event
ATOPP / July 13-15, 2023
Connect with us in New Orleans at the Advanced Topics for Oncology Pharmacy Professionals show.
Learn MoreConnect with us in New Orleans at the Advanced Topics for Oncology Pharmacy Professionals show.
Previous slide
Next slide
BioSpecialized™
Devoted to life-changing treatments
Our focus is simple, but our work is complex: making advanced, life-changing biologic medicines more accessible to more patients.
At Fresenius Kabi, we bring deep expertise in complex medicines, state-of-the-art supply chain and manufacturing capabilities, and above all, exceptional customer support to everything we do. That’s why our approach is BioSpecialized™.
Making life-changing therapies more affordable.
The Problem: The high cost of biologics.1

2% of people in the
U.S. use biologics

Biologics make up 40%
of total prescription drug
spending
The Solution: Biosimilars can potentially offer up to 30% price reductions when compared with reference products.2
- lnserro A. Enzi, Hassan introduce bipartisan bill to improve biosimilar education. American Journal of Managed Care (AJMC). Published May 27, 2019. Accessed May 20, 2022. https://www.centerforbiosimilars.com/view/enzi-hassan-introduce-bipartisan-bill-to-improve-biosimilar-education
- Kabir ER, Moreino SS, Siam MKS. The breakthrough of biosimilars: A twist In the narrative of biological therapy. Biomolecules. 2019;9{9):410. https://pubmed.ncbi.nlm.nih.gov/31450637/
We have launched biosimilars in Europe, Australia and Canada, turning the promise of
effective and affordable biologic therapies into reality for many patients. And, with an
extensive portfolio of intravenous and injectable medicines, plus over 100 years of
pharmaceutical experience and innovation, we are ideally positioned to deliver the
benefits of biosimilars to you and your patients.
Advanced science, manufacturing and support for biosimilars